Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360051 | 0.87 | TRPV1 (0.44) | TRPV1MAPK3 | |
| SCHEMBL4362095 | 0.85 | TRPV1 (0.56) | TRPV1MAPK3 | |
| SCHEMBL4359911 | 0.84 | TRPV1 (0.44) | TRPV1MAPK3 | |
| SCHEMBL4355010 | 0.84 | TRPV1 (0.48) | TRPV1MAPK3 | |
| SCHEMBL4358524 | 0.84 | TRPV1 (0.51) | TRPV1MAPK3 | |
| SCHEMBL4352833 | 0.82 | TRPV1 (0.52) | TRPV1MAPK3 | |
| SCHEMBL4908576 | 0.82 | TRPV1 (0.48) | TRPV1MAPK3 | |
| SCHEMBL4354994 | 0.81 | TRPV1 (0.57) | TRPV1MAPK3 | |
| SCHEMBL13622817 | 0.81 | TRPV1 (0.68) | TRPV1MAPK3 | |
| SCHEMBL13622816 | 0.80 | TRPV1 (0.60) | TRPV1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070203133-A1 | Substituted 5,12-diaza-benzoanthracene analogues | NEUROGEN CORPORATION (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| CN-1953979-A | Substituted 5, 12-diaza-benzoanthracene analogues | NEUROGEN CORP (US) | 2007-04-25 | — | — | CN | disclosed |
| CN-1878771-A | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORP (US) | 2006-12-13 | — | — | CN | disclosed |
| EP-1723145-A2 | SUBSTITUTED 5,12-DIAZA-BENZOANTHRACENE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1678173-A2 | 4-HETEROBICYCLYLAMINO-SUBSTITUTED QUINAZOLINES AND ANALOGUES THEREOF AS CAPSAICIN-ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1644372-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005086968-A2 | SUBSTITUTED 5,12-DIAZA-BENZOANTHRACENE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| WO-2005023807-A2 | 4 - HETEROBICYCLYAMINO - SUBSTITUTED QUINAZOLINES AND ANALOGUES THEROF AS CAPSAICIN - ANTAGONISTS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005007652-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | PIGS, HRH4, GPR35 | TRPV1 244/4885MAPK3 3017/4885 |
| US-20070203133-A1 | Substituted 5,12-diaza-benzoanthracene analogues | GPR52, SUCNR1, MC1R | TRPV1 246/4885MAPK3 3743/4885 |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR52 | TRPV1 279/4885MAPK3 3351/4885 |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | PIGS, HRH4, GPR52 | TRPV1 281/4885MAPK3 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.